Riskpilot← Back to searchSign inGet full accessSynAct Pharma AB
ABActiveOrg 5590584826Scheelevägen 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20161-4 employees
Revenue 2024
SEK 7M
-16% vs 2023
EBITDA margin
-320.8%
+3% vs 2023
Equity ratio
93.6%
Financial strength
Net profit 2024
SEK -90,6M
+39% vs 2023
| Revenue | SEK 7M | -16% |
| EBITDA | SEK -22,4M | +3% |
| Net profit | SEK -90,6M | +39% |
| Total assets | SEK 257,8M | +12% |
| Equity | SEK 241,4M | +13% |
| Employees | — | — |
Legal name
SynAct Pharma AB
Org number
5590584826
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 april 2016
Share capital
SEK 5 811 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna eller en av dem i förening med Westberg, Björn Uno Bernhard Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet skall vara att utveckla och kommersialisera läkemedel för behandling av inflammation och andra sjukdomar och därmed förenlig verksamhet samt att äga och förvalta aktier.
Address
Scheelevägen 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 1 287 | 1 697 | 1 637 | 5 144 | 8 262 | 6 969 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −4 262 | −17 940 | −4 591 | −8 185 | −6 643 | −10 962 | −20 671 | −23 018 | −22 359 |
| Depreciation & amort. | −0 | −252 | −0 | −0 | −0 | −0 | — | — | — |
| EBIT | −4 262 | −18 192 | −4 591 | −8 185 | −6 643 | −10 962 | −20 671 | −23 018 | −22 359 |
| Net financials | 46 | 155 | 187 | −1 847 | −65 624 | −50 010 | −111 420 | −126 510 | −70 310 |
| Profit before tax | −4 216 | −18 036 | −4 390 | −9 999 | −72 267 | −60 966 | −130 970 | −149 529 | −90 623 |
| Tax | −0 | 2 641 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 216 | −15 395 | −4 390 | −9 999 | −72 267 | −60 966 | −130 970 | −149 529 | −90 623 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 39 372 | 15 225 | 52 558 | 76 993 | 31 068 | 45 334 | 119 225 | 230 768 | 257 757 |
| Equity | 38 813 | 12 912 | 51 519 | 68 432 | 26 971 | 40 404 | 111 127 | 214 072 | 241 360 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 821 | 8 304 |
| Short-term debt | 559 | 2 313 | 1 039 | 8 561 | 4 097 | 4 930 | 8 098 | 7 876 | 8 093 |
| Total debt | 559 | 2 313 | 1 039 | 8 561 | 4 097 | 4 930 | 8 098 | 16 697 | 16 397 |
EBITDA margin
-320.8%
This company
15.8%
Market median
-2130% vs market
20162024
Equity ratio
93.6%
This company
38.2%
Market median
+145% vs market
20162024
Return on equity
-37.5%
This company
18.4%
Market median
-304% vs market
20162024
Net profit margin
-1300.4%
This company
8.1%
Market median
-16154% vs market
20162024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20162024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-04-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PR External Signatory | External Signatory | 2022 | — | — |
JØ Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
MH Authorized Recipient of Service | Authorized Recipient of Service | 2020 | — | — |
LM Chief Auditor | Chief Auditor | 2020 | — | — |
BU External Signatory | External Signatory | 2023 | — | — |
TB Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
BA External Signatory | External Signatory | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SynAct Pharma AB (this company)
TXP PHARMA AGSynact Pharma ApsTxp Pharma AgSYNACT PHARMA APSBoard members of SynAct Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patrik Renblad | External Signatory | 0 companies |
| Jeppe Øvli Øvlesen | Chief Executive Officer | 0 companies |
| Malin Helena Wikstrand | Authorized Recipient of Service | 0 companies |
| Linda Margareta Bengtsson | Chief Auditor | 0 companies |
| Björn Uno Bernhard Westberg | External Signatory | 0 companies |
| Torbjörn Bjerke | Chief Executive Officer | 0 companies |
| Bengt Anders Ekenberg | External Signatory | 0 companies |
| Sten Scheibye | Board of Directors | 0 companies |
| Thomas Jonassen | Board of Directors | 0 companies |
| Maj Kerstin Hasselgren | Board of Directors | 0 companies |
| Sten Randahl Sörensen | Board of Directors | 0 companies |
| Torbjörn Bjerke | Chairman | 0 companies |
| Anders Kronborg | Chairman | 0 companies |
| Marina S Bozilenko | Board of Directors | 0 companies |
| Nils Thomas von Koch | Board of Directors | 0 companies |
| Uli Alf Hacksell | Chairman | 0 companies |
| Jeppe Ragnar Andersen | Board of Directors | 0 companies |
| John Haurum | Board of Directors | 0 companies |
| Henrik Stage | Board of Directors | 0 companies |
| Terje Kalland | Board of Directors | 0 companies |